Literature DB >> 15838631

Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers.

Inmaculada Ros1, Luisa Alvarez, Nuria Guañabens, Pilar Peris, Ana Monegal, Ivonne Vázquez, Dacia Cerdá, Antonio M Ballesta, José Muñoz-Gómez.   

Abstract

In this study, we analyzed the changes in biochemical markers of bone turnover in five patients with hypophosphatemic osteomalacia. The following bone markers were evaluated: among bone formation markers, total alkaline phosphatase (TAP), bone alkaline phosphatase (BAP), osteocalcin (bone Gla protein, BGP) and procollagen type I N propeptide (PINP); among bone resorption markers, serum beta C-terminal cross-linked telopeptide of type I collagen (s-CTx), urinary hydroxyproline (HYP), and N-terminal and alpha and beta C-terminal cross-linked telopeptides of collagen (NTx and alpha- and beta-CTx). In addition, the alpha/beta-CTx ratio was evaluated. TAP and BAP were the markers with the highest increase in both frequency and magnitude. Conversely, BGP values were low in all patients. Collagen-related markers were slightly increased in nearly half of the patients. Among them, PINP showed the highest proportion of increased values. The alpha/beta-CTx ratio was within normal values in all patients. In conclusion, TAP and BAP seem to be the best bone markers in the diagnostic evaluation of hypophosphatemic osteomalacia. In addition, their high values associated with low levels of BGP provide an even more reliable biochemical profile of this disorder, when associated with the classic mineral and skeletal homeostasis abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838631     DOI: 10.1007/s00774-004-0594-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  6 in total

1.  High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K.

Authors:  A F Schilling; C Mülhausen; W Lehmann; R Santer; T Schinke; J M Rueger; M Amling
Journal:  Osteoporos Int       Date:  2007-01-06       Impact factor: 4.507

2.  Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.

Authors:  Yuki Nagata; Yasuo Imanishi; Akira Ishii; Masafumi Kurajoh; Koka Motoyama; Tomoaki Morioka; Hiroshi Naka; Katsuhito Mori; Takami Miki; Masanori Emoto; Masaaki Inaba
Journal:  Endocrine       Date:  2011-08-06       Impact factor: 3.633

3.  Osteomalacia revisited : a report on 28 cases.

Authors:  Laia Gifre; Pilar Peris; Ana Monegal; Maria Jesús Martinez de Osaba; Luisa Alvarez; Núria Guañabens
Journal:  Clin Rheumatol       Date:  2010-10-15       Impact factor: 2.980

4.  Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment.

Authors:  M P Mosti; G Flemmen; J Hoff; A K Stunes; U Syversen; E Wang
Journal:  Osteoporos Int       Date:  2015-10-26       Impact factor: 4.507

5.  Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.

Authors:  Malachi J McKenna; Julie Martin-Grace; Rachel Crowley; Patrick J Twomey; Mark T Kilbane
Journal:  J Bone Miner Metab       Date:  2018-09-20       Impact factor: 2.626

6.  Management of bone disease in cystinosis: Statement from an international conference.

Authors:  Katharina Hohenfellner; Frank Rauch; Gema Ariceta; Atif Awan; Justine Bacchetta; Carsten Bergmann; Susanne Bechtold; Noelle Cassidy; Geroges Deschenes; Ewa Elenberg; William A Gahl; Oliver Greil; Erik Harms; Nadine Herzig; Bernd Hoppe; Christian Koeppl; Malcolm A Lewis; Elena Levtchenko; Galina Nesterova; Fernando Santos; Karl P Schlingmann; Aude Servais; Neveen A Soliman; Guenther Steidle; Clodagh Sweeney; Ulrike Treikauskas; Rezan Topaloglu; Alexey Tsygin; Koenraad Veys; Rodo V Vigier; Jozef Zustin; Dieter Haffner
Journal:  J Inherit Metab Dis       Date:  2019-08-05       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.